ARTICLE | Company News

FDA approves Daklinza for HCV genotype 3

July 28, 2015 2:53 AM UTC

FDA approved Daklinza daclatasvir from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) to treat HCV genotype 3. BMS spokesperson Robert Perry said BMS expects to launch Daklinza within a week at a list price of $63,000 for a 12-week course. ...